Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated March 04, 2026, titled "Glenmark Specialty SA Receives U.S. FDA Approval for Fluticasone Propionate Inhalation Aerosol USP, 44 mcg per actuation, with 180-Day Competitive Generic Therapy Exclusivity".
GLENMARK · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Glenmark's subsidiary Glenmark Specialty SA has received final U.S. FDA approval for Fluticasone Propionate Inhalation Aerosol USP, 44 mcg per actuation, a generic version of GlaxoSmithKline's FloVent HFA. The product has been granted Competitive Generic Therapy (CGT) designation, making Glenmark the 'first approved applicant' and eligible for 180 days of market exclusivity upon launch. Distribution in the U.S. will begin in March 2026 through Glenmark Pharmaceuticals Inc., USA. According to IQVIA data, the FloVent HFA 44 mcg market had annual U.S. sales of approximately $520.1 million for the 12 months ending January 2026. The approval strengthens Glenmark's respiratory portfolio in the U.S. market.
This is a positive development for Glenmark shareholders. The 180-day CGT exclusivity means Glenmark will likely be the sole generic supplier in this ~$520 million U.S. market for the first six months, which could translate to strong revenue and margin contribution. Near-term stock sentiment should be supportive, though the actual financial impact will depend on pricing, market share capture, and the post-exclusivity competitive landscape.